Melasma-Review of Current Treatment Modalities and Efficacy Assessment of a New ResorcinolBased Topical Formulation

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.16966/2576-2826.116
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Proposing Melasma Severity Index: A New, More Practical, Office-based Scoring System for Assessing the Severity of Melasma

  2016cited by this paper
• Assessment of efficacy, safety, and tolerability of 4-n-butylresorcinol 0.3% cream: an Indian multicentric study on melasma

  2016cited by this paper
• Heterogeneous Pathology of Melasma and Its Clinical Implications

  2016cited by this paper
• Recent progress in melasma pathogenesis

  2015cited by this paper
• Melasma: clinical diagnosis and management options

  2015influential reference
• Evidence-Based Treatment for Melasma: Expert Opinion and a Review

  2014influential reference
• Melasma update

  2014cited by this paper
• Exogenous ochronosis: case report and literature review.

  2012cited by this paper
• Topical 5% tranexamic acid for the treatment of melasma in Asians: A double-blind randomized controlled clinical trial

  2012cited by this paper
• MELASMA: A CLINICO-EPIDEMIOLOGICAL STUDY OF 312 CASES

  2011cited by this paper
• Transcriptional profiling shows altered expression of wnt pathway- and lipid metabolism-related genes as well as melanogenesis-related genes in melasma.

  2011cited by this paper
• The Efficacy and Safety of 4-n-butylresorcinol 0.1% Cream for the Treatment of Melasma: A Randomized Controlled Split-face Trial.

  2010cited by this paper
• Treatment of melasma with oral administration of tranexamic acid

  2008cited by this paper
• Solar elastosis and presence of mast cells as key features in the pathogenesis of melasma

  2008cited by this paper
• The vascular characteristics of melasma.

  2007cited by this paper
• Evaluation of efficacy and safety of rucinol serum in patients with melasma: a randomized controlled trial

  2007cited by this paper
• Localized Intradermal Microinjection of Tranexamic Acid for Treatment of Melasma in Asian Patients: A Preliminary Clinical Trial

  2006cited by this paper
• The dermal stem cell factor and c‐kit are overexpressed in melasma

  2006cited by this paper
• Inhibitory effects of 4-n-butylresorcinol on tyrosinase activity and melanin synthesis.

  2005influential reference
• Modulation of vascular endothelial growth factor receptors in melanocytes

  2005cited by this paper
• Intense Pulsed Light for the Treatment of Refractory Melasma in Asian Persons

  2004cited by this paper
• Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients.

  1998cited by this paper
• Physiological changes in the skin during pregnancy.

  1997cited by this paper
• Topical tretinoin (retinoic acid) improves melasma. A vehicle‐controlled, clinical trial

  1993cited by this paper
• The Treatment of Melasma 20% Azelaic Acid versus 4% Hydroquinone Cream

  1991cited by this paper
• Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma.

  1989cited by this paper
• Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study.

  1981cited by this paper

• Clinical evaluation of anti‐aging effects of combined therapy—Azelaic acid, phytic acid, and vitamin C applied layer by layer in females with Fitzpatrick skin types II and III

  2022cites this paper
• A randomized controlled clinical trial to evaluate safety and efficacy of a Unani formulation in the management of Kalaf (Melasma)

  2021cites this paper
• The Difference of Melanin Index in Treatment of MelasmaUsing Non-Hydroquinone Cream and Kligman's Formula

  2020cites this paper